
<!DOCTYPE html>
<html>
<head>
    <meta charset="utf-8">
    <title>Extracted Sections</title>
</head>
<body>
<section class="overview">
 <div class="breadcrumbs">
  <a href="/earnings">
   Earnings Analysis
  </a>
  <span>
   â€º
  </span>
  <a href="/company/ABBV">
   AbbVie (ABBV)
  </a>
 </div>
 <h1>
  AbbVie's $823 Million Pipeline Bet Lowers EPS Guidance
 </h1>
 <div class="meta">
  <a class="tag" href="/company/ABBV">
   ABBV
  </a>
 </div>
</section>
<section class="summary">
 <h2 class="multiColumn">
  <span>
   Summary
  </span>
  <div class="timestampBox">
   <time class="small" datetime="2025-07-03 17:07:55 +0000" title="Published">
    Jul 3, 2025
   </time>
  </div>
 </h2>
 AbbVie, a global pharmaceutical leader known for treatments like Humira, recently announced a significant pre-tax acquired IPR&amp;D (in-process research and development) and milestones expense of $823 million for the second quarter of 2025. This substantial investment in external innovation is a critical move for the company to replenish its drug pipeline and mitigate potential revenue declines from upcoming patent expirations, particularly for its blockbuster immunology drug, Humira.
 <br/>
 <br/>
 The $823 million expense is set to unfavorably impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.42. As a direct consequence, AbbVie has revised its full-year 2025 adjusted diluted EPS guidance range to $11.67 - $11.87. The adjusted diluted EPS guidance for the second quarter of 2025 is now set at $2.84 - $2.88.
 <br/>
 <br/>
 This strategic outlay underscores AbbVie's commitment to securing long-term revenue streams through the acquisition or licensing of new drug candidates and technologies. In the pharmaceutical sector, a robust pipeline is essential for sustained growth, and this proactive approach signals an active strategy to acquire high-potential assets that could drive future performance.
 <br/>
 <br/>
 However, this investment comes with an immediate trade-off: a dilution of short-term earnings, which may weigh on investor sentiment. A key challenge highlighted by AbbVie is its policy of not forecasting acquired IPR&amp;D and milestones expenses due to their uncertain occurrence and timing. This introduces an element of unpredictability to future earnings, as substantial charges related to external innovation could recur, potentially obscuring underlying operational performance and making it harder for analysts to model earnings accurately. This lack of forward visibility creates a degree of earnings volatility.
</section>
<section class="internalAdBox">
 <h2 class="multiColumn">
  <span>
   AI Headshots
  </span>
  <span class="small">
   Sponsored
  </span>
 </h2>
 <div>
  Turn 3 selfies into professional photos with
  <a href="https://hotpot.ai/ai-headshots" target="_blank">
   AI Headshots
  </a>
  .
 </div>
 <div>
  Happiness guaranteed.
  <a href="https://hotpot.ai/ai-headshots" target="_blank">
   Learn more
  </a>
  .
 </div>
 <a class="link group" href="https://hotpot.ai/ai-headshots" target="_blank">
  <div class="imageList">
   <img alt="AI headshot" loading="lazy" src="https://hotpot.ai/images/site/ai/photoshoot/corporate_headshot/style_gallery/5.webp"/>
   <img alt="AI professional headshot" loading="lazy" src="https://hotpot.ai/images/site/ai/photoshoot/corporate_headshot/style_gallery/29.webp"/>
   <img alt="AI LinkedIn photo" loading="lazy" src="https://hotpot.ai/images/site/ai/photoshoot/corporate_headshot/style_gallery/35.webp"/>
   <img alt="AI corporate headshot" loading="lazy" src="https://hotpot.ai/images/site/ai/photoshoot/corporate_headshot/style_gallery/17.webp"/>
   <img alt="AI executive picture" loading="lazy" src="https://hotpot.ai/images/site/ai/photoshoot/corporate_headshot/style_gallery/12.webp"/>
   <img alt="AI headshot" loading="lazy" src="https://hotpot.ai/images/site/ai/photoshoot/corporate_headshot/style_gallery/33.webp"/>
   <img alt="AI corporate headshot" loading="lazy" src="https://hotpot.ai/images/site/ai/photoshoot/corporate_headshot/style_gallery/1.webp"/>
   <img alt="AI LinkedIn photo" loading="lazy" src="https://hotpot.ai/images/site/ai/photoshoot/corporate_headshot/style_gallery/26.webp"/>
   <img alt="AI executive picture" loading="lazy" src="https://hotpot.ai/images/site/ai/photoshoot/corporate_headshot/style_gallery/41.webp"/>
  </div>
 </a>
</section>
<section>
 <h2>
  What Big Flaw Do Uber Bulls and Duolingo Shorts Miss?
 </h2>
 <p>
  For Uber, investors miss that profits are concentrated in 20 metro markets.
 </p>
 <p>
  <a href="/bears">
   See why
  </a>
  this matters, and what else Wall Street overlooks with Duolingo, Kohl's, and other popular stocks.
 </p>
</section>
<section>
 <h2>
  ABBV Bear vs. Bull in 30 Seconds
 </h2>
 <p>
  See our
  <a href="/company/ABBV">
   ABBV earnings
  </a>
  articles for Bear vs. Bull summaries, found in 10-Q/10-K reports.
 </p>
</section>
<section class="feed">
 <h2>
  ABBV Executive Quotes
 </h2>
 <p>
  See what
  <a href="/quotes/ABBV">
   AbbVie
  </a>
  executives said in press releases, transcripts, and financial results.
 </p>
</section>
<section>
 <h2>
  Key Facts
 </h2>
 <ul>
  <li>
   Acquired IPR&amp;D and milestones expense: AbbVie expects to report a pre-tax acquired IPR&amp;D and milestones expense of $823 million for the second quarter of 2025. This significant expense reflects investment in external innovation, which is critical for pipeline replenishment in the pharmaceutical industry.
  </li>
  <li>
   EPS guidance revision: This expense will unfavorably impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.42. Consequently, the full-year 2025 adjusted diluted EPS guidance range is revised to $11.67 - $11.87, and the second quarter 2025 adjusted diluted EPS guidance is set at $2.84 - $2.88.
  </li>
 </ul>
</section>
<section>
 <h2>
  Red Flags
 </h2>
 <ul>
  <li>
   -
  </li>
 </ul>
</section>
<section>
 <h2>
  Strategic Implications
 </h2>
 <ul>
  <li>
   Pipeline investment strategy: The $823 million IPR&amp;D and milestones expense signals AbbVie's aggressive strategy to bolster its pipeline through external collaborations, licensing, and asset acquisitions. This approach is essential for long-term growth and mitigating revenue declines from patent expirations, particularly for its key drug Humira. It indicates a strategic trade-off: immediate earnings dilution for potential future growth drivers.
  </li>
  <li>
   Uncertainty in R&amp;D expenses: AbbVie explicitly states it does not forecast acquired IPR&amp;D and milestones expense due to the uncertainty of future occurrences and timing. This introduces a degree of unpredictability to future earnings as substantial charges related to external innovation could recur, leading to unexpected earnings revisions and potentially obscuring underlying operational performance.
  </li>
 </ul>
</section>
<section>
 <h2>
  Key Positives
 </h2>
 <ul>
  <li>
   Commitment to pipeline replenishment: The $823 million acquired IPR&amp;D and milestones expense demonstrates AbbVie's commitment to investing in new drug candidates and technologies. This proactive approach is crucial in the pharmaceutical sector to maintain a robust pipeline and secure long-term revenue streams, especially as major patent expirations approach. It signals an active strategy to acquire high-potential assets that could drive future growth.
  </li>
 </ul>
</section>
<section>
 <h2>
  Key Negatives
 </h2>
 <ul>
  <li>
   Downward EPS guidance revision: The primary negative is the direct impact of the $823 million pre-tax IPR&amp;D expense, which led to a $0.42 reduction in both Q2 and full-year adjusted diluted EPS guidance. This immediate dilution of short-term earnings can weigh on investor sentiment, as it reflects a trade-off where long-term, uncertain pipeline benefits are prioritized over near-term profitability metrics.
  </li>
  <li>
   Unpredictable earnings volatility: The company's stance of not forecasting IPR&amp;D expenses means that investors face a recurring risk of unexpected, significant charges that can materially impact earnings per share. This lack of forward visibility on a potentially large and recurring expense creates volatility and makes it harder for analysts to model earnings accurately, potentially leading to discount factors in valuation.
  </li>
 </ul>
</section>
<section>
 <h2>
  Full Earnings Prep
 </h2>
 <ul>
  <li>
   Details of acquired assets: What specific drug candidates or technologies were acquired or licensed for the $823 million IPR&amp;D expense? What is their stage of development (e.g., preclinical, Phase 1, Phase 2), target indications, and competitive landscape? Understanding the quality and strategic fit of these assets is crucial for assessing their long-term value creation potential.
  </li>
  <li>
   Strategic rationale and pipeline impact: How do these new assets fit into AbbVie's broader pipeline strategy, especially regarding the post-Humira growth trajectory? Does management foresee these acquisitions materially accelerating growth or diversifying the company's therapeutic areas, and what are the specific milestones for these assets?
  </li>
  <li>
   Cash flow implications: How did the $823 million cash outflow for IPR&amp;D impact operating cash flow and free cash flow for the quarter? This is important for understanding the company's liquidity and ability to fund continued external innovation alongside its internal R&amp;D efforts and dividend payments.
  </li>
 </ul>
</section>
<section>
 <h2>
  More Information
 </h2>
 <ul>
  <li>
   ABBV analysis:
   <a href="/company/ABBV" target="_blank">
    AbbVie (ABBV) news and earnings
   </a>
  </li>
  <li>
   ABBV share price:
   <a href="https://finance.yahoo.com/quote/ABBV?s=panabee" target="_blank">
    Yahoo!
   </a>
   -
   <a href="https://seekingalpha.com/symbol/ABBV?s=panabee" target="_blank">
    Seeking Alpha
   </a>
  </li>
  <li>
   ABBV financials:
   <a href="https://www.gurufocus.com/stock/ABBV/summary?s=panabee" target="_blank">
    Guru Focus
   </a>
   -
   <a href="https://finance.yahoo.com/quote/ABBV/financials?s=panabee" target="_blank">
    Yahoo!
   </a>
  </li>
  <li>
   <a href="https://www.sec.gov/Archives/edgar/data/0001551152/000155115225000034/abbv-20250703.htm" target="_blank">
    AbbVie 8-K
   </a>
  </li>
  <li>
   <a href="https://www.sec.gov/Archives/edgar/data/0001551152/000155115225000034/abbv-20250630nonxgaapxex991.htm" target="_blank">
    AbbVie Guidance including impact of acquired IPR&amp;D and milestones expense
   </a>
  </li>
 </ul>
</section>
<section class="faq">
 <h2>
  AbbVie Earnings Guidance FAQ
 </h2>
 <ul>
  <li>
   <h3>
    Why is this newsworthy?
   </h3>
   <p>
    AbbVie revised its financial guidance for full-year 2025 and the second quarter of 2025 due to an unexpected $823 million pre-tax acquired IPR&amp;D and milestones expense. This adjustment to financial guidance is highly newsworthy to elite investors.
   </p>
  </li>
  <li>
   <h3>
    What significant expense will AbbVie report for Q2 2025?
   </h3>
   <p>
    A pre-tax acquired IPR&amp;D and milestones expense of $823 million.
   </p>
  </li>
  <li>
   <h3>
    How will this expense affect AbbVie's Q2 and full-year earnings per share?
   </h3>
   <p>
    It will unfavorably impact both GAAP and adjusted non-GAAP diluted EPS by $0.42.
   </p>
  </li>
  <li>
   <h3>
    What is the revised full-year 2025 adjusted diluted EPS guidance?
   </h3>
   <p>
    $11.67 - $11.87.
   </p>
  </li>
  <li>
   <h3>
    What is the Q2 2025 adjusted diluted EPS guidance?
   </h3>
   <p>
    $2.84 - $2.88.
   </p>
  </li>
  <li>
   <h3>
    Why is AbbVie incurring this significant expense?
   </h3>
   <p>
    To bolster its pipeline through external innovation, crucial for long-term growth and mitigating revenue declines from patent expirations like Humira.
   </p>
  </li>
  <li>
   <h3>
    What is the strategic implication of this expense?
   </h3>
   <p>
    It signals an aggressive strategy to acquire high-potential assets, trading immediate earnings dilution for potential future growth drivers.
   </p>
  </li>
  <li>
   <h3>
    Does AbbVie forecast acquired IPR&amp;D and milestones expenses?
   </h3>
   <p>
    No, due to the uncertainty of future occurrences and timing, which introduces unpredictability to future earnings.
   </p>
  </li>
 </ul>
</section>
<section>
 <h2>
  Licensing
 </h2>
 <p>
  Our FAQs may be redistributed for online commercial purposes, provided you link back to Panabee.com and provide attribution.
					Link and attribution must occur on every page displaying our content, and above our content.
					For licensing other content, please contact us.
 </p>
</section>
<section id="freeAnalysis">
 <h2>
  Free Analysis
 </h2>
 <p>
  We check
  <a href="/bears">
   stock ideas
  </a>
  for possible blindspots. We also analyze earnings, presentations, news, dividends, and other stock events.
 </p>
 <p>
  To celebrate our launch, analysis is free until July 31st.
 </p>
 <p>
  Tag us on Twitter or Reddit to trigger free analysis on any topic. To keep requests private, request via DM.
 </p>
 <p>
  Twitter/X:
  <a href="https://x.com/PanabeeAI" target="_blank">
   @PanabeeAI
  </a>
 </p>
 <p>
  Reddit:
  <a href="https://www.reddit.com/user/panabee_ai" target="_blank">
   @u/panabee_ai
  </a>
 </p>
 <p>
  Follow on
  <a href="https://x.com/panabeeAI">
   Twitter/X
  </a>
  or
  <a href="https://www.reddit.com/r/PanabeeAI" target="_blank">
   Reddit
  </a>
  for updates.
 </p>
</section>
<section>
 <h2>
  Disclosure
 </h2>
 <p>
  Our content is powered by AI and rarely involves an editor. This content may contain unintentional errors and omissions, especially with numbers. Our information is a starting point for
					independent research, not a recommendation to act.
 </p>
 <p>
  Do not act on our information. This is not investment advice. This is not legal advice. Investing is risky and may cause severe financial loss.
					We are not licensed advisors. Despite our best efforts, analysis and forward-looking statements may be wrong. Verify everything. See
  <a href="/disclaimer">
   full disclaimer
  </a>
  .
 </p>
 <p>
  We may take financial positions after detecting mispricings. These conflicts are disclosed on articles where we have a direct position. While these positions stem from genuine opinions, they may be inadvertently wrong.
 </p>
</section>
<section class="internalAdBox">
 <h2>
  AI Headshots
 </h2>
 <div class="disclaimer">
  Sponsored
 </div>
 <div>
  Turn 3 selfies into professional photos with
  <a href="https://hotpot.ai/ai-headshots" target="_blank">
   AI Headshots
  </a>
  .
 </div>
 <div>
  Happiness guaranteed.
  <a href="https://hotpot.ai/ai-headshots" target="_blank">
   Learn more
  </a>
  .
 </div>
 <a class="link group" href="https://hotpot.ai/ai-headshots" target="_blank">
  <div class="imageList">
   <img alt="AI headshot" loading="lazy" src="https://hotpot.ai/images/site/ai/photoshoot/corporate_headshot/style_gallery/5.webp"/>
   <img alt="AI professional headshot" loading="lazy" src="https://hotpot.ai/images/site/ai/photoshoot/corporate_headshot/style_gallery/29.webp"/>
   <img alt="AI LinkedIn photo" loading="lazy" src="https://hotpot.ai/images/site/ai/photoshoot/corporate_headshot/style_gallery/35.webp"/>
   <img alt="AI corporate headshot" loading="lazy" src="https://hotpot.ai/images/site/ai/photoshoot/corporate_headshot/style_gallery/17.webp"/>
   <img alt="AI executive picture" loading="lazy" src="https://hotpot.ai/images/site/ai/photoshoot/corporate_headshot/style_gallery/12.webp"/>
   <img alt="AI headshot" loading="lazy" src="https://hotpot.ai/images/site/ai/photoshoot/corporate_headshot/style_gallery/33.webp"/>
   <img alt="AI corporate headshot" loading="lazy" src="https://hotpot.ai/images/site/ai/photoshoot/corporate_headshot/style_gallery/1.webp"/>
   <img alt="AI LinkedIn photo" loading="lazy" src="https://hotpot.ai/images/site/ai/photoshoot/corporate_headshot/style_gallery/26.webp"/>
   <img alt="AI executive picture" loading="lazy" src="https://hotpot.ai/images/site/ai/photoshoot/corporate_headshot/style_gallery/41.webp"/>
  </div>
 </a>
</section>
<section>
 <div class="title">
  Old Panabee
 </div>
 <ul>
  <li>
   <a href="/domain-name-search">
    Domain Name Search
   </a>
  </li>
  <li>
   <a href="/business-name-generator">
    Business Name Generator
   </a>
  </li>
  <li>
   <a href="/app-name-generator">
    App Name Generator
   </a>
  </li>
  <li>
   <a href="/news/why-is-cuda-such-a-powerful-moat-for-nvidia-nvda">
    What is Nvidia's Secret Moat?
   </a>
  </li>
  <li>
   <a href="/news/how-will-deepseek-impact-nvidia">
    How will DeepSeek Impact Nvidia?
   </a>
  </li>
  <li>
   <a href="/news/how-will-the-u-s-strategic-bitcoin-reserve-impact-coinbase">
    Will the Bitcoin Reserve Hurt Coinbase?
   </a>
  </li>
  <li>
   <a href="/company/NVDA">
    NVDA Stock Analysis
   </a>
  </li>
  <li>
   <a href="/news/what-happens-to-microstrategy-if-bitcoin-crashes">
    MicroStrategy Bitcoin Crash Analysis
   </a>
  </li>
  <li>
   <a href="/bear/uber-ackman-cash-flow-av-fears-growth-levers-mispriced-long-06162025">
    Ackman's Uber Bet: AV Fears Overblown?
   </a>
  </li>
  <li>
   <a href="https://hotpot.ai/blog/ai-thoughts">
    AI Misinformation
   </a>
  </li>
 </ul>
</section>
<section>
 <div class="title">
  Industry News
 </div>
 <ul>
  <li>
   <a href="/tariffs">
    Tariffs
   </a>
  </li>
  <li>
   <a href="/quotes">
    Notable Quotes
   </a>
  </li>
  <li>
   <a href="/industry/ai">
    AI News
   </a>
  </li>
  <li>
   <a href="/industry/biotech">
    Biotech News
   </a>
  </li>
  <li>
   <a href="/industry/crypto">
    Crypto News
   </a>
  </li>
  <li>
   <a href="/industry/semiconductor">
    Semiconductor News
   </a>
  </li>
  <li>
   <a href="/fda">
    FDA News
   </a>
  </li>
  <li>
   <a href="/industry/retail-e-commerce" style="display:none">
    Retail &amp; E-Commerce News
   </a>
  </li>
  <li>
   <a href="/industry/cloud-infrastructure">
    Cloud Infrastructure News
   </a>
  </li>
  <li>
   <a href="/industry/enterprise-software">
    Enterprise Software News
   </a>
  </li>
  <li>
   <a href="/bear/duolingo-short-google-ai-translation-impacts-language-learning-06112024">
    What Key Flaw Do Duolingo Shorts Miss?
   </a>
  </li>
 </ul>
</section>
<section>
 <div class="title">
  AI Image Tools
 </div>
 <ul>
  <li>
   <a href="https://hotpot.ai/colorize-picture">
    Colorize Photo
   </a>
  </li>
  <li>
   <a href="https://hotpot.ai/remove-background">
    Remove Background
   </a>
  </li>
  <li>
   <a href="https://hotpot.ai/upscale-photo">
    Upscale Photo
   </a>
  </li>
  <li>
   <a href="https://hotpot.ai/blog/ai-art-and-image-generator-guide">
    Generating Images using AI
   </a>
  </li>
  <li>
   <a href="https://hotpot.ai/ai-avatar">
    AI Avatar
   </a>
  </li>
  <li>
   <a class="leaf" href="https://hotpot.ai/bing-ai-image-generator-alternative">
    Bing AI Image Generator Alternative
   </a>
  </li>
 </ul>
</section>
<section>
 <div class="title">
  AI Image Generators
 </div>
 <ul>
  <li>
   <a class="leaf" href="https://hotpot.ai/ai-headshots" target="_blank">
    AI Headshots
   </a>
  </li>
  <li>
   <a class="leaf" href="https://hotpot.ai/ai-image-generator" target="_blank">
    AI Image Generator
   </a>
  </li>
  <li>
   <a class="leaf" href="https://hotpot.ai/art-generator" target="_blank">
    AI Art Generator
   </a>
  </li>
  <li>
   <a class="leaf" href="https://hotpot.ai/ai-stock-photo" target="_blank">
    AI Stock Photos
   </a>
  </li>
  <li>
   <a href="https://hotpot.ai/logo-generator">
    Logo Generator
   </a>
  </li>
  <li>
   <a href="https://hotpot.ai/ai-character-generator">
    AI Character Generator
   </a>
  </li>
  <li>
   <a href="https://hotpot.ai/anime-generator">
    Anime Generator
   </a>
  </li>
 </ul>
</section>

</body>
</html>
